ÂÜÀòÂÒÂ×

Ruhi Khan is the current head of business development at Adastra Pharmaceuticals. Ruhi has held this position since January 2019. Prior to that, they were the head of business development at Tempest Therapeutics from January 2019 to December 2021. Khan has also served as the vice president of business development at Acorda Therapeutics from January 2009 to December 2014 and the senior director of business development at Lexicon Pharmaceuticals from January 2005 to December 2009. From October 2002 to June 2005, they were the director of business development and finance at EnVivo Pharmaceuticals. Khan has also worked as a business development and finance consultant for multiple biotechnology companies from January 2015 to December 2021. Prior to that, they were an analyst at Axon Group from January 1997 to December 1998.

Ruhi Khan has a Bachelor's degree in Biology from Harvard University and an MBA in Finance and Healthcare Management from The Wharton School.

Their manager is Scott Megaffin, CEO. They work with Ralph E. Christoffersen - Director, Stuart Gallant - Head, Pharmaceutical Manufacturing, and Kristan Meetze - Head, Tumor Biology.